Mark Stein, PhD, ABPP

Personal Statement

I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to  our behavioral group treatment programs and treatment recommendations.   The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves  diagnostic evaluations and consultations  for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for  individuals with ADHD.    I have  assisted in the development of several stimulant  and non stimulant medications, and participated in many clinical trials. Currently, we are   conducting a study  for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication  and  behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD,  and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.

Education

Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago

Department Affiliations

Other Affiliations

PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic

 

Center for Child Health, Behavior, and Development

 

Brotman Baty Institute

Recent Publications

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
(2024 Feb 28)
Prostate Cancer Prostatic Dis
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES

A new schizophrenia screening instrument based on evaluating the patient's writing.
(2024 Feb 23)
Schizophr Res 266(): 127-135
Peng Z, Li Q, Liu X, Zhang H, Luosang-Zhuoma, Ran M, Liu M, Tan X, Stein MJ

The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer.
(2024 Jan 1)
Endocr Oncol 4(1): e230015
Stein MS, Kalff V, Williams SG, Murphy DG, Colman PG, Hofman MS

Longitudinal Patterns of Community-Based Treatment Utilization Among Ethnically and Racially Diverse Adolescents with Attention-Deficit/Hyperactivity Disorder.
(2024 Feb 2)
J Child Adolesc Psychopharmacol
Hill DM, Sibley MH, Stein MA, Leviyah X

Longitudinal Stability of Neural Correlates of Pediatric Attention Deficit Hyperactivity Disorder: A Pilot Study of Event Related Potentials and Electroencephalography.
(2024 Feb)
J Atten Disord 28(4): 493-511
Peisch V, Rutter TM, Sargent C, Oommen R, Stein MA, Arnett AB

Show complete publication list »
Edit Profile